The Europe bladder cancer therapeutics & diagnostic market is segmented based on:
Transitional cell bladder cancer
Invasive bladder cancer
Superficial bladder cancer
Squamous cell bladder cancer
Other rare types
Bladder cancer is the 5th most common cancer in Europe, with more than 151,000 new cases diagnosed in 2012 (4% of the total). Bladder cancer incidence rates are the highest in Southern Europe. In Europe (2012), the highest world age-standardised incidence rates for bladder cancer are in Belgium for men and Hungary for women; the lowest rates are in the United Kingdom for men and the Ukraine for women.
Some of the key participants in the industry include Pfizer, GlaxoSmithKline, Sanofi S.A, Roche, Novartis, Eli Lilly and Co, AstraZeneca plc, Bristol-Myers Squibb etc.
Increasing bladder cancer cases
Drug innovations with regard to the bladder cancer
Rise in aging populace
Advanced health care services
Upsurge in awareness about bladder diseases and their available therapies in the market
Increasing health care expenditure
Rise in the number of patent expirations
Rise in the use of generic drugs
Asymptomatic nature of the disease
SPECIALITIES OF THIS REPORT
The report will be useful in gaining an exhaustive understanding of the regional market. It will also be of assistance in providing a comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.
The report will be an ideal source material for industry consultants, manufacturers and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.
The report contains wide range of information about the leading market players and the major strategies adopted by them.
WHAT THE REPORT OFFERS
Market definition along with identification of key drivers and restraints for the market.
Market analysis with region specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.
Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
1.1 Market Definition
1.2 Research Methodology
1.3 Markets Covered
2. Executive Summary
3. Market Overview
3.1 Market Drivers
3.1.1 Rise in awareness about bladder diseases and their available therapies
3.1.2 Increasing health care expenditure
3.1.3 Innovation in drug development, and subsequent technological advancements
3.2 Market Restraints
3.2.1 Rise in number of patent expirations
3.2.2 Increase in use of generic drugs
3.2.3 Asymptomatic nature of the disease
3.3 Market Opportunitites
3.4 Market Threats
4. Porters Five Force Analysis
4.1 Bargaining Power of suppliers
4.2 Bargaining power of buyers
4.3 Degree of competition
4.4 Threat of substitution
4.5 Threat of new entrants
5. Market Segmentation
5.1 Europe Bladder Cancer Therapeutics & Diagnostics Market, by Cancer Type
5.1.1 Transitional Cell Bladder Cancer
5.1.2 Superficial Bladder Cancer
5.1.3 Invasive bladder cancer
5.1.4 Squamous cell bladder cancer
5.1.5 Other rare types
5.2 Europe Bladder Cancer Therapeutics Market
5.2.3 Radiation therapy
5.3 Europe Bladder Cancer Diagnostics Market
5.3.4 Urine Cytology
5.3.5 Bladder Ultrasound
5.4 Europe Bladder Cancer Therapeutics & Diagnostics Market, By Region
5.4.6 Rest Of Europe
6. Competitive Landscape
6.1 Mergers & Acquisitions
6.2 Agreements, Collaborations & Partnerships
6.3 New Product Launches
6.4 Recommendations to new market players
7. Company Profiles
7.1 Novartis International AG
7.2 Pfizer Inc
7.3 GlaxoSmithKline plc
7.4 Sanofi S.A
7.5 Eli Lilly and Co
7.6 AstraZeneca plc
7.7 Bristol-Myers Squibb
7.8 F. Hoffmann-La Roche AG
7.9 Celgene Corporation